Baxter Highlights First Carbon Trust Certification for Medical Product

Baxter - As part of its efforts to advance product stewardship and sustainable practices in manufacturing, Baxter recently received Carbon Reduction certification from the UK-based Carbon Trust for FLEXBUMIN [Albumin (Human)] -- the first and only albumin therapy in a flexible, plastic container, and the first and only medical product to receive this certification...FLEXBUMIN received certification from the Carbon Trust based on a verification of comparative carbon footprint analyses combined with a commitment by Baxter to continue to decrease the carbon footprint of FLEXBUMIN during the next two years. The analyses were conducted in accordance with the BSI PAS 2050 Standard for product carbon footprinting and quantified the greenhouse gas emissions associated with the 50ml and 100ml FLEXBUMIN and BUMINATE container systems and transportation, from resource extraction through end-of-life.

"As the first and only medical product in the world to receive the carbon footprint certification from the Carbon Trust, it is clear that Baxter has a strong commitment to sustainable product design and manufacturing practices," said Tom Delay, chief executive of the Carbon Trust. "This certification reflects Baxter's continuous commitment to further reduce its carbon footprint."